AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18676140
Drug: Bec2 (2.5mg)/BCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bec2 (2.5mg)/BCG vaccine arm (VA)
Trial: 16014329
Drug: Escitalopram 5
RxNorm normalized name: escitalopram 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 5 mg
Trial: 25733175
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents with stent length < 20 mm
Trial: 25733175
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents with stent length ≥ 20 mm
Trial: 21194775
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nateglinide and GLP‐1 derivatives
Trial: 14550939
Drug: Fluoxetine 10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10‐20 mg alone
Trial: 14550939
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol patch 0.1‐0.2 mg alone
Trial: 14550939
Drug: Fluoxetine 10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10‐20 mg and estradiol patch 0.1‐0.2 mg (combination treatment)
Trial: 10441772
Drug: Pharmaceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatment for osteoporosis
Trial: 8537805
Drug: Albuterol 4
RxNorm normalized name: albuterol 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 4 mg by mouth three times daily for 7 days
Trial: 1794242
Drug: Enoxacin tablets
DrugBank: Enoxacin (DB00467)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enoxacin tablets
Trial: 1794242
Drug: Enoxacin capsules
DrugBank: Enoxacin (DB00467)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enoxacin capsules
Trial: 31340321
Drug: Lumbar oblique-pulling
RxNorm normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar oblique-pulling manipulation in combination with sling-exercise-therapy training
Trial: 31340321
Drug: Sling-exercise-therapy training
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling-exercise-therapy training
Trial: 26337246
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (TXA) administered as a bolus dose of 15 mg/kg 10 minutes before tourniquet inflation and an infusion of 10 mg/kg/h for 3 hours post-operation
Trial: 21644186
Drug: Brief strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief strategic therapy
Trial: 21644186
Drug: Minimal supportive
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal supportive therapy
Trial: 11065206
Drug: 5-HT3-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT3-receptor antagonists
Trial: 11065206
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol and 5-HT3-receptor antagonists
Trial: 9302301
Drug: 6.4 mg
RxNorm normalized name: menthol 6.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation
Trial: 9302301
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of zanamivir by inhalation
Trial: 9302301
Drug: Zanamivir groups
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir groups (both inhaled and intranasal)
Trial: 9302301
Drug: Zanamivir (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (inhaled and intranasal)
Trial: 7508055
Drug: Indapamide (IND,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (IND, 2.5 mg/day)
Trial: 7508055
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 25 mg/day)
Trial: 7508055
Drug: Nifedipine (NFD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (NFD, 40 mg/day)
Trial: 7508055
Drug: Enalapril (ENL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (ENL, 20 mg/day)
Trial: 7508055
Drug: Atenolol (ATL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (ATL, 100 mg/day)
Trial: 2834478
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin, fragmine (5,000 anti‐Xa U/24 h)
Trial: 2834478
Drug: Standard heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin, calciparin (5,000 IU/8 h)
Trial: 2834478
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin, fragmine
Trial: 23545929
Drug: 3 new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 new skin brightener formulations containing SMA‐432
Trial: 16984739
Drug: Pycnogenol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (1 mg/kg body weight/day)
Trial: 14559692
Drug: Modified FLAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FLAG regimen (n=10): Fludarabine (50 mg/d, VDx5 d) and Ara‐C (200 mg/d, VDx5 or 7 d)
Trial: 14559692
Drug: Classic FLAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic FLAG regimen (n=6): Fludarabine (50 mg/d, VDx5d), Ara‐C (500 or 1,000 mg/d, VDx5d) and G‐CSF (300 microg/d, x5 d)
Trial: 10691817
Drug: Oxybutynin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin with salivary stimulant pastilles
Trial: 24393627
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Program (OHP) participation (G1)
Trial: 24393627
Drug: No Oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Oral Health Program participation (G2)
Trial: 21705063
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment of multiple cardiovascular risk factors
Trial: 16530576
Drug: Oral melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral melphalan and prednisone plus thalidomide (MPT)
Trial: 16530576
Drug: Oral melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral melphalan and prednisone (MP) alone
Trial: 12767550
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg conjugated equine estrogens (CEE)
Trial: 12767550
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogens (CEE)
Trial: 8334330
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ganciclovir/kg 3 times a week (group A)
Trial: 8334330
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg ganciclovir/kg once daily for 5 days a week (group B)
Trial: 21186923
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of modafinil (once daily)
Trial: 16934861
Drug: Party drug
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Party drug use (alcohol, cannabis, ecstasy, cocaine)
Trial: 16934861
Drug: Psychological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological and social problems related to party drug use
Trial: 12063485
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation
Trial: 9430602
Drug: Globin digest
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Globin digest 1 g
Trial: 9430602
Drug: Globin digest
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Globin digest 4 g
Trial: 1907551
Drug: Insulin‐induced hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐induced hypoglycaemia with concomitant alpha‐adrenoceptor blockade
Trial: 1907551
Drug: Insulin‐induced hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐induced hypoglycaemia with total autonomic blockade (alpha‐adrenoceptor blockade combined with beta‐adrenoceptor blockade and atropine)
Trial: 1907551
Drug: Insulin‐induced hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐induced hypoglycaemia without any autonomic blockade
Trial: 21554143
Drug: Alendronate plus
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate plus alfacalcidol (combination therapy)
Trial: 21554143
Drug: Alendronate alone
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate alone (monotherapy)
Trial: 17237735
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) use
Trial: 15017896
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, day first, and Gemcitabine 1250 mg/m2, day 8, every 3 weeks, total 3 cycles plus fractionated radiation therapy (40-46 Gy) for stage IIIa (N2) and IIIb patients.
Trial: 15017896
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, every three weeks, total 4 cycles without fractionated radiation therapy for stage IV patients.
Trial: 11698931
Drug: Probiotic therapy;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy; specific strains not mentioned, dosage and duration not specified.
Trial: 27859588
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy and Client-centered therapy
Trial: 24947717
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy at discharge (n = 6,873)
Trial: 24947717
Drug: No-beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-beta-blocker therapy at discharge (n = 1,637)
Trial: 24947717
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy after propensity-score matching (n = 1,325)
Trial: 22737708
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily for 6 weeks
Trial: 10561182
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Trial: 30630790
Drug: Yousiyue (Drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yousiyue (Drospirenone and Ethinylestradiol tablets) plus comprehensive nursing intervention program
Trial: 30630790
Drug: General routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General routine nursing and treatment (Control)
Trial: 14716693
Drug: Donepezil (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (2.5-10 mg/day)
Trial: 16973667
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily for 10 weeks (groups 1 and 2)
Trial: 11871208
Drug: Organisational interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Organisational interventions (e.g., central computerised tracking systems, nurses contacting patients)
Trial: 11245034
Drug: Intracarotid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracarotid infusion of papaverine and BCNU (250 mg)
Trial: 7698589
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg daily)
Trial: 31625252
Drug: Haemorrhoid energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemorrhoid energy therapy (HET)
Trial: 21635995
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (levodopa 200 mg/benserazide 50 mg)
Trial: 21635995
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (branded formulation)
Trial: 12616141
Drug: Suppressive valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive valacyclovir therapy
Trial: 11206638
Drug: Clarithromycin 100
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 100 mg (group A)
Trial: 11206638
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg (group B)
Trial: 29695590
Drug: Opicapone 25
RxNorm normalized name: opicapone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 25 mg once daily for 1 week, followed by tailored levodopa and/or opicapone dose adjustments
Trial: 26985797
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (Eylea) 2 mg every 4 weeks (2q4)
Trial: 26985797
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (Eylea) 2 mg every 8 weeks (2q8)
Trial: 26985797
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) 0.5 mg every 4 weeks (Rq4)
Trial: 25392635
Drug: Clonidine infusion
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine infusion (group I)
Trial: 25392635
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (group II)
Trial: 25392635
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (group III)
Trial: 20188604
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G potassium troches (50 mg), applied 4 times per day for 4 days
Trial: 8557216
Drug: Terguride (TER)
RxNorm normalized name: terguride
DrugBank: Terguride (DB13399)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Terguride (TER) 2 mg/day
Trial: 23403883
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose (20 mg iron and 100 μg folic acid)
Trial: 23403883
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose doubled (40 mg iron and 200 μg folic acid)
Trial: 23403883
Drug: Weekly dose
RxNorm normalized name: XPOVIO 60 MG Weekly Dose Carton Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly dose (40 mg iron and 200 μg folic acid)
Trial: 20963434
Drug: BG-12 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (240 mg orally three times daily for 24 weeks)
Trial: 11161392
Drug: Third generation
RxNorm normalized name: Third generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third generation chemotherapy regimens
Trial: 2890546
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg immediately after dinner
Trial: 2890546
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg 3 hours after dinner
Trial: 2890546
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg immediately after dinner
Trial: 2890546
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg 3 hours after dinner
Trial: 30584220
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA 1.8 g/day)
Trial: 20574136
Drug: Bezafibrate (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200-400 mg/day)
Trial: 16364159
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 microg once daily
Trial: 17640111
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 microg once daily (in subgroup of very severe COPD)
Trial: 17640111
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 microg once daily (in subgroup of high healthcare utilization)
Trial: 373260
Drug: Cimetidine 1000
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1000 mg daily for 4 weeks
Trial: 11482588
Drug: Health Care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Care Financing Administration's pilot Medicare & You 1999 handbook
Trial: 2729315
Drug: Bendrofluazide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide + Albuterol
Trial: 2729315
Drug: Bendrofluazide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide + Albuterol (Women)
Trial: 21256000
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) and intravenous ZOL (4 mg, q4 wks) for 3 months
Trial: 21256000
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) alone
Trial: 8884050
Drug: Smokers not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smokers not exposed to chemical compounds
Trial: 8884050
Drug: Non-smokers not
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-smokers not exposed to chemical compounds
Trial: 1733001
Drug: Other medications
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other medications used commonly for secondary prophylaxis
Trial: 6704282
Drug: Nifedipine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (single sublingual dose)
Trial: 31416472
Drug: Post-treatment period
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment period (6h after treatment)
Trial: 29960852
Drug: KetoCal® (4:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KetoCal® (4:1 ketogenic ratio formula), 8-ounce (237 mL) daily for the first month
Trial: 20188444
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin 1g every 12h or antistaphylococcal penicillin 2g every 4h, both with gentamicin 1mg/kg every 8h for the first 4 days)
Trial: 17659004
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral Polypodium leucotomos three times daily with NB-UVB twice weekly
Trial: 17659004
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with NB-UVB twice weekly
Trial: 16195287
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 600 microg
Trial: 8615488
Drug: Dimenhydrinate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 0.5 mg/kg intravenously
Trial: 6146006
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir 200 mg four times a day
Trial: 30640697
Drug: Intravenous oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous oxaliplatin 75 mg/m2 on day 1 and intraperitoneal docetaxel 75 mg/m2 on day 2
Trial: 27812501
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture plus fluoxetine
Trial: 27812501
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture plus fluoxetine
Trial: 20200268
Drug: Sergliflozin etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sergliflozin etabonate 500 mg